Bank of America reiterated its Buy rating and increased its price target for McKesson (MCK) to $622 following the company’s strong third-quarter fiscal year 2024 results. The company exceeded expectations with revenue of $79 billion and adjusted EPS of $7.04, driven by growth across all segments. BofA anticipates continued strong performance, largely due to demand for GLP-1 drugs and potential operating expense leverage.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
BofA remains bullish on McKesson (MCK) following strong third quarter performance
Bank of America reiterated its Buy rating and increased its price target for McKesson (MCK) to $622 following the company’s strong third-quarter fiscal year 2024 results. The company exceeded expectations with revenue of $79 billion and adjusted EPS of $7.04, driven by growth across all segments. BofA anticipates continued strong performance, largely due to demand for GLP-1 drugs and potential operating expense leverage.